Fasenra Dosage/Direction for Use

Posology: The recommended dose is 30 mg of FASENRA by subcutaneous injection every 4 weeks for the first 3 doses, and then every 8 weeks thereafter.
FASENRA is intended for long-term treatment. A decision to continue the therapy should be made at least annually based on disease severity, level of exacerbation control and blood eosinophil counts.
Paediatric population: Available data of FASENRA in adolescents aged 12 to less than 18 years are described in Pharmacology: Pharmacodynamics under Actions, however no posology recommendations can be made.
The safety and efficacy of FASENRA in children aged less than 12 years have not been established.
Elderly patients: No dose adjustment is required for elderly patients (see Pharmacology: Pharmacokinetics under Actions).
Renal and hepatic impairment: No dose adjustment is required for patients with renal or hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Method of administration: FASENRA is administered as a subcutaneous injection. In line with clinical practice, monitoring of patients after administration of biologic agents is recommended (see Hypersensitivity Reactions under Precautions).
Administer FASENRA into the thigh, or abdomen. If somebody else administers the injection, the upper arm can also be used. Do not administer into areas where the skin is tender, bruised, erythematous, or hardened.
After proper training in the subcutaneous injection technique and education about signs and symptoms of hypersensitivity reactions (see Precautions), patients or their caregivers may administer Fasenra if their physician determines that it is appropriate, with medical follow-up as necessary. Proper training in subcutaneous injection technique using the autoinjector (FASENRA PEN) should be provided according to the 'Instructions for Use' under Cautions for Usage.